Journal of Medicinal Chemistry
Article
(6) (a) Osborne, C. K.; Monaco, M. W.; Lippman, M. E.; Kahn, C. R.
Correlation among insulin binding, degredation, and biological activity in
human breast cancer cells in long-term tissue culture. Cancer Res. 1978, 38,
94−102. (b) Kaaks, R.; Toniolo, P.; Akhmedkhanov, A.; Lukanova, A.;
Biessy, C.; Dechaud, H.; Rinaldi, S.; Zeleniuch-Jacquotte, A.; Shore, R. E.;
Riboli, E. Serum C-peptide, insulin-like growth factor (IGF)-I IGF-binding
proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. 2000, 92,
1592−1600. (c) Belfiore, A.; Malaguarnera, R. Insulin receptor and cancer.
Endocr.-Relat. Cancer 2011, 18, R125−R147. (d) Belfiore, A.; Frasca, F.;
Pandini, G.; Sciacca, L.; Vigneri, R. Insulin receptor isoforms and insulin
receptor/insulin-like growth factor receptor hybrids in physiology and
disease. Endocr. Rev. 2009, 30, 586−623.
(7) (a) Koontz, J. W.; Iwahashi, M. Insulin as a potent, specific growth
factor in rat hepatoma cell line. Science 1981, 211, 947−949.
(b) Massague, J.; Blinderman, L. A.; Czech, M. P. The high affinity
insulin receptor mediates growth stimulation in rat hepatoma cells. J.
Biol. Chem. 1982, 257, 3958−3963.
(8) (a) Frittitta, L.; Cerrato, A.; Sacco, M. G.; Weidner, N.; Goldfine, I.
D.; Vigneri, R. The insulin receptor content is increased in breast cancers
initiated by three different oncogens in transgenic mice. Breast Cancer
Res. Treat. 1997, 45, 141. (b) Belfiore, A.; Frittitta, L.; Costantino, A.;
Frasca, F.; Pandini, G.; Sciacca, L.; Goldfine, I. D.; Vigneri, R. Insulin
receptors in breast cancer. Ann. N.Y. Acad. Sci. 1996, 784, 173−188.
(c) Webster, N. J. G.; Resnik, J. L.; Reichart, D. B.; Strauss, B.; Haas, M.;
Seely, B. L. Repression of the insulin receptor promoter by the tumor
suppressor gene product p53: a possible mechanism for receptor
overexpression in breast cancer. Cancer Res. 1996, 56, 2781−2788.
(d) Mulligan, A. M.; O’Mally, F. P.; Ennis, M.; Fantus, G.; Goodwin, P. J.
Insulin receptor is an independent predictor of a favorable outcome in
early stage breast cancer. Breast Cancer Res. Treat. 2007, 106, 39−47.
(e) Novosyadlyy, R.; Lann, D. E.; Vijayakumar, A.; Rowzee, A.;
Lazzarino, D. A.; Fierz, Y.; Carboni, J. M.; Gottardis, M. M.; Pennisi, P.
A.; Molinolo, A. A.; Kurshan, N.; Mejia, W.; Santopietro, S.; Yakar, S.;
Wood, T. L.; LeRoith, D. Insulin-mediated acceleration of breast cancer
development and progression in a nonobese model of type 2 diabetes.
Cancer Res. 2010, 70, 741−51. (f) Zhang, H.; Pelzer, A. M.; Kiang, D. T.;
Yee, D. Down-regulation of type I insulin-like growth factor receptor
increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007, 67,
391−397. (g) Papa, V.; Pezzino, V.; Costantino, A.; Belfiore, A.;
Giuffrida, D.; Frittitta, L.; Vannelli, G. B.; Brand, R.; Goldfine, I. D.;
Vigneri, R. Elevated insulin receptor content in human breast cancer. J.
Clin. Invest. 1990, 86, 1503−1510.
for radioimmunoassay: Comparison of lactoperoxidase and chloramine-
T iodination. J. Nucl. Med. 1978, 19, 900−905. (b) Jorgensen, K. H.;
Larsen, U. D. Homogenous mono[125I] insulins: Preparation and
characterization of mono-[125I]-(Tyr A14)- and mono-[125I]-(Tyr
A19)-insulin. Diabetologica 1980, 19, 546−554. (c) Rissler, K.;
Engelmann, P. Labeling of insulin with non-radioactive 127I and
application to incorporation of radioactive 125I for use in receptor
binding experiments by high-performance liquid chromatography. J.
Chromatogr., Biomed. Appl. 1996, 679, 21−29.
(13) (a) Kurtaran, A.; Li, S. R.; Raderer, M.; Leimer, M.; Muller, C.;
̈
Pidlich, J.; Neuhold, N.; Hubsch, P.; Angelberger, P.; Scheithauer, W.;
̈
Virgolini, I. Technetium-99m-galactosyl-neoglycoalbumin combined
with iodine-123-tyr-(A14)-insulin visualizes human hepatocellular
carcinomas. J. Nucl. Med. 1995, 36, 1875−1881. (b) Hachiya, H. L.;
Treves, S. I.; Kahn, C. R.; Sodoyez, J. C.; Sodoyez-Goffaux, F. Altered
insulin distribution and metabolism in type I diabetics assessed by [123I]
insulin scanning. J. Clin. Endocrinol. Metab. 1987, 64, 801−808.
(c) Sodoyez, J. C.; Sodoyez-Goffaux, F.; Guillaume, M.; Merchie, G.
[
123I]-Insulin metabolism in normal rats and humans. External detection
by a scintillation camera. Science 1983, 219, 865−867.
(14) (a) Glaser, M.; Brown, D. J.; Law, M. P.; Iozzo, P.; Waters, S. L.;
Poole, K.; Knickmeier, M.; Camici, P. G.; Pike, V. W. Preparation of no-
carrier-added [124I]A14-iodoinsulin as a radiotracer for positron
emission tomography. J. Labelled Compd. Radiopharm. 2001, 44, 465−
480. (b) Iozzo, P.; Osman, S.; Glaser, M.; Knickmeier, M.; Ferrannini,
E.; Pike, V. W.; Camici, P. G.; Law, M. P. In vivo imaging of insulin
receptors by PET: preclinical evaluation of iodine-125 and iodine-124
labelled human insulin. Nucl. Med. Biol. 2002, 29, 73−82.
(15) (a) Eastman, R. C.; Carson, R. E.; Jacobson, K. A.; Shai, Y.;
Channing, M. A.; Dunn, B. B.; Bacher, J. D.; Baas, E.; Jones, E.; Kirk, K.
L.; Lesniak, M. A.; Roth, J. In vivo imaging of insulin receptors in
monkeys using 18F-labelled insulin and positron emission tomography.
Diabetes 1992, 41, 855−860. (b) Shai, Y.; Kirk, K. L.; Channing, M. A.;
Dunn, B. B.; Lesniak, M. A.; Eastman, R. C.; Finn, R. D.; Roth, J.;
Jacobson, K. A. 18F-Labeled insulin: a prosthetic group methodology for
incorporation of a positron emitter into peptides and proteins.
Biochemistry 1989, 28, 4801−4806. (c) Guenther, K. J.; Yoganathan,
S.; Garofalo, R.; Kawabata, T.; Strack, T.; Labiris, R.; Dolovich, M.;
Chirakal, R.; Valliant, J. F. Synthesis and in vitro evaluation of 18F- and
19F-labeled insulin: A new radiotracer for PET-based molecular imaging
studies. J. Med. Chem. 2006, 49, 1466−1474.
(16) Sundararajan, C.; Besanger, T. R.; Labiris, R.; Guenther, K. J.; Strack,
T.; Garafalo, R.; Kawabata, T. T.; Finco-Kent, D. F.; Zubieta, J.; Babich, J.
W.; Valliant, J. F. Synthesis and characterization of rhenium and
technetium-99m labeled insulin. J. Med. Chem. 2010, 53, 2612−2621.
(9) Ulanet, D. B.; Ludwig, D. L.; Kahn, C. R.; Hanahan, D. Insulin
receptor functionally enhances multistage tumor progression and
conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Nat.
Acad. Sci. U.S.A. 2010, 107, 10791−10798.
(10) (a) Baserga, R. The decline and fall of the IGF-I receptor. J. Cell.
Physiol. 2013, 228, 675−679. (b) Zhang, Y.; Cai, W. Molecular imaging
of insulin-like growth factor 1 receptor in cancer. Am. J. Nucl. Med. Mol.
Imaging 2012, 2, 248−259. (c) Pollak, M. Insulin and insulin-like growth
factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8, 915−928.
(d) Siddle, K. Signalling by insulin and IGF receptors: Supporting acts
and new players. J. Mol. Endocrinol. 2011, 47, R1−R10.
(17) (a) Wester, H.-J.; Hamacher, K.; Stocklin, G. A comparative study
̈
of N.C.A. fluorine-18 labeling of proteins via acylation and photo-
chemical conjugation. Nucl. Med. Biol. 1996, 23, 365−372. (b) Kuchar,
M.; Pretze, M.; Kniess, T.; Steinbach, J.; Pietzsch, J.; Loser, R. Site-
selective radiolabeling of peptides by (18)F-fluorobenzoylation with
[(18F)]SFB in solution and on solid phase: a comparative study. Amino
Acids 2012, 43, 1431−1443.
(18) Chen, Y.; Pullambhatla, M.; Foss, C. A.; Byun, Y.; Nimmagadda,
S.; Srinivasan, S.; Sgouros, G.; Mease, R. C.; Pomper, M. G. 2-(3-{1-
Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-urei-
do)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging
agent for prostate cancer. Clin. Cancer Res. 2011, 17, 7645−7653.
(19) Haka, M. S.; Kilbourn, M. R.; Watkins, G. L.; Toorongian, S. A.
Aryltrimethylammonium trifluoromethanesulfonates as precursors to
aryl [18F]fluorides: improved synthesis of [18F]GBR-13119. J. Labelled
Compd. Radiopharm. 1989, 27, 823−833.
(20) Simms, R. W.; Kim, D. H.; Weaver, D. M.; Sundararagan, C.;
Blacker, M.; Stephenson, K. A.; Valliant, J. F. Emulsion reactors: a new
technique for the preparation of molecular imaging probes. Chem.Eur.
J. 2012, 18, 6746−6749.
(21) Sodoyez, J. C.; Sodoyez-Goffaux, F. R.; Moris, Y. M. 125I-insulin:
kinetics of interaction with its receptors and rate of degredation in vivo.
Am. J. Physiol. Endocrinol. Metab. 1980, 239, E3−E8.
(11) (a) Haluska, P.; Carboni, J. M.; Loegering, D. A.; Lee, F. Y.; Wittman,
M.; Saulnier, M. G.; Frennesson, D. B.; Kalli, K. R.; Conover, C. A.; Attar, R.
M.; Kaufmann, S. H.; Gottardis, M.; Erlichman, C. In vitro and in vivo
antitumor effects of the dual insulin-like growth factor-I/insulin receptor
inhibitor, BMS-554417. Cancer Res. 2006, 66, 362−371. (b) Law, J. H.;
Habibi, G.; Hu, K.; Masoudi, H.; Wang, M. Y. C.; Stratford, A. L.; Park, E.;
Gee, J. M. W.; Finlay, P.; Jones, H. E.; Nicholson, R. I.; Carboni, J.;
Gottardis, M.; Pollak, M.; Dunn, S. E. Phosphorylated insulin-like growth
factor-I/insulin receptor is present in all breast cancer subtypes and is
related to poor survival. Cancer Res. 2008, 68, 10238−10246. (c) Sachdev,
D.; Singh, R.; Fujita-Yamaguchi, Y.; Yee, D. Down-regulation of insulin
receptor by antibodies against the type I insulin-like growth factor receptor:
Implications for anti-insulin-like growth factor therapy in breast cancer.
Cancer Res. 2006, 66, 2391−2402.
(12) (a) Wajchenberg, B. L.; Pinto, H.; Torres de Toledo e Souza, I.;
Lerario, A. C.; Pieroni, R. R. Preparation of iodine-125-labeled insulin
I
dx.doi.org/10.1021/jm401020c | J. Med. Chem. XXXX, XXX, XXX−XXX